443 related articles for article (PubMed ID: 24456909)
1. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A
Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep--A randomized, placebo-controlled trial.
Kasper S; Anghelescu I; Dienel A
Eur Neuropsychopharmacol; 2015 Nov; 25(11):1960-7. PubMed ID: 26293583
[TBL] [Abstract][Full Text] [Related]
3. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.
Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Dienel A; Schläfke S
Int Clin Psychopharmacol; 2010 Sep; 25(5):277-87. PubMed ID: 20512042
[TBL] [Abstract][Full Text] [Related]
4. Silexan does not cause withdrawal symptoms even when abruptly discontinued.
Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A; Kasper S
Int J Psychiatry Clin Pract; 2017 Sep; 21(3):177-180. PubMed ID: 28319423
[TBL] [Abstract][Full Text] [Related]
5. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.
Woelk H; Schläfke S
Phytomedicine; 2010 Feb; 17(2):94-9. PubMed ID: 19962288
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial.
Kasper S; Volz HP; Dienel A; Schläfke S
Eur Neuropsychopharmacol; 2016 Feb; 26(2):331-340. PubMed ID: 26718792
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis.
Yap WS; Dolzhenko AV; Jalal Z; Hadi MA; Khan TM
Sci Rep; 2019 Dec; 9(1):18042. PubMed ID: 31792285
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Dienel A; Schläfke S
Wien Med Wochenschr; 2010 Dec; 160(21-22):547-56. PubMed ID: 21170695
[TBL] [Abstract][Full Text] [Related]
9. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review.
Kasper S
Int J Psychiatry Clin Pract; 2013 Nov; 17 Suppl 1():15-22. PubMed ID: 23808618
[TBL] [Abstract][Full Text] [Related]
10. Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set.
Kasper S; Möller HJ; Volz HP; Schläfke S; Dienel A
Int Clin Psychopharmacol; 2017 Jul; 32(4):195-204. PubMed ID: 28379882
[TBL] [Abstract][Full Text] [Related]
11. Silexan in anxiety disorders: Clinical data and pharmacological background.
Kasper S; Müller WE; Volz HP; Möller HJ; Koch E; Dienel A
World J Biol Psychiatry; 2018 Sep; 19(6):412-420. PubMed ID: 28511598
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials.
Dold M; Bartova L; Volz HP; Seifritz E; Möller HJ; Schläfke S; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1615-1628. PubMed ID: 36717399
[TBL] [Abstract][Full Text] [Related]
13. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.
Möller HJ; Volz HP; Dienel A; Schläfke S; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2019 Mar; 269(2):183-193. PubMed ID: 29150713
[TBL] [Abstract][Full Text] [Related]
15. Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders: A symptom-based, patient-level analysis of randomized, placebo-controlled trials.
Dold M; Möller HJ; Volz HP; Seifritz E; Schläfke S; Bartova L; Kasper S
Eur Psychiatry; 2024 Mar; 67(1):e23. PubMed ID: 38425206
[TBL] [Abstract][Full Text] [Related]
16. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of Silexan on sleep are mediated by its anxiolytic effect.
Seifritz E; Schläfke S; Holsboer-Trachsler E
J Psychiatr Res; 2019 Aug; 115():69-74. PubMed ID: 31121394
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited.
Bartova L; Dold M; Volz HP; Seifritz E; Möller HJ; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):51-63. PubMed ID: 35262795
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
